Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.

Jing Pan,Yue Tan,Guoling Wang,Biping Deng,Zhuojun Ling,Weiliang Song,Samuel Seery,Yanlei Zhang,Shuixiu Peng,Jinlong Xu,Jiajia Duan,Zelin Wang,Xinjian Yu,Qinlong Zheng,Xiuwen Xu,Ying Yuan,Fangrong Yan,Zhenglong Tian,Kaiting Tang,Jiecheng Zhang,Alex H. Chang,Xiaoming Feng

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.

2021

PURPOSEPatients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen recept...

Keywords:

Chimeric antigen receptor
poor prognosis
Cancer research
Medicine
donor derived
first in human
Refractory
Antigen
Lymphoblastic Leukemia
T cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations